Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
IG1-H5263 | Human | Human IGF-I Protein, Fc Tag (MALS verified) |
|
||
IG1-H82Q6 | Human | Biotinylated Human IGF-I Protein, His,Avitag™ (SPR verified) |
|
||
IG1-H5245 | Human | Human IGF-I Protein, His Tag (SPR verified) |
|
||
IG1-M5253 | Mouse | Mouse IGF-I Protein, Fc Tag (MALS verified) |
|
||
IG1-H82F7 | Human | Biotinylated Human IGF-I Protein, Avitag™,Fc Tag (MALS verified) |
|
Biotinylated Human IGF-I Protein, His,Avitag™ (SPR verified) (Cat.No. IG1-H82Q6) stimulates the proliferation of Human IGF-1 R (Luc) HEK293 Reporter Cell. The EC50 for this effect is 0.1746 µg/mL. (Routinely tested)
Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-I, His,Avitag (Cat. No. IG1-H82Q6) with an affinity constant of 68 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ACT-01 | ACT-01; OCS-05; BN-201; G-79 | Phase 2 Clinical | Promius Pharma | Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases | Details |
Xentuzumab | BI-836845 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Dusigitumab | MEDI-573 | Phase 2 Clinical | Medimmune Llc | Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular | Details |
ACT-01 | ACT-01; OCS-05; BN-201; G-79 | Phase 2 Clinical | Promius Pharma | Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases | Details |
Xentuzumab | BI-836845 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Dusigitumab | MEDI-573 | Phase 2 Clinical | Medimmune Llc | Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.